MSMikhail Aizikovich Sherman

Mikhail Aizikovich Sherman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mikhail Aizikovich Sherman has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discoradicular conflict: vicious circles of the inflammatory model

    by M. A. Kovalev, Ковалев М. А., M. A. Sherman, Шерман М. А., S. V. Muravev, Муравьев С. В., G. Z. Kloyan, Клоян Г. З., I. D. Shitoev, Шитоев И. Д.

    Literature data from open sources (eLibrary, Scopus, Web of Science, PubMed) were analyzed and summarized with no limitations on search depth. The search was conducted using the following keywords: dorsopathy, inflammation, disc extrusion, disc herniation, discogenic radiculopathy, dorsopathy, disc inflammation. Analysis of the obtained data suggests the formation of a new perspective on the problem of inflammation in the area of discogenic radiculopathy through the segregation of certain findings into isolated “paradoxes” or “vicious circles” of the described problem, thereby expanding the epistemological horizons of the pathogenesis of dorsopathies. Aseptic inflammation in the intervertebral disc area is a multiphase process that includes preclinical biomechanical imbalance, the onset of dorsopathy, and the phase of extrusion formation and resolution. The development of inflammation is associated with the contact spread of immune and neuroinflammatory reactions to neural structures, along with simultaneous activation of reparative mechanisms. The proposed approach makes it possible to substantiate preventive and therapeutic strategies aimed at accelerating the resolution of the pathological process.

  • Open Access

    Results of medical and social research and assessment of quality of life in myasthenia gravis

    by Ya. V. Vlasov, Yu. A. Merkulov, V. M. Alifirova, M. V. Ambroskina, K. Z. Bakhtiyarova, S. B. Blinova, Z. A. Goncharova, N. Yu. Gorokhova, I. V. Greshnova, L. G. Zaslavsky, et al.

    Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.


  • Open Access

    Clinical and social study and assessment of quality of life in patients with neuromyelitis optica spectrum disorders

    by Yu. V. Vlasov, V. M. Alifirova, N. N. Babicheva, K. Z. Bakhtiyarova, O. V. Bragina, Z. A. Goncharova, N. Yu. Gorokhova, I. V. Greshnova, O. V. Dzundza, E. A. Dubchenko, et al.

    Neuromyelitis optica spectrum disorders (NMOSD, formerly known as opticoneuromyelitis or Devic's disease) are severe chronic autoimmune inflammatory diseases of the central nervous system (CNS) associated with high disability in the absence of adequate treatment. In Russia, no assessment of the medical and social characteristics of this disease and the quality of life of patients has been conducted, which complicates the assessment of the prognosis and the development of medical and social management strategies for these patients.Objective: to analyse the medical and social characteristics and quality of life of patients diagnosed with NMOSD (opticoneuromyelitis).Material and methods. The condition of patients with a confirmed diagnosis of NMOSD or opticoneuromyelitis was assessed using a specially designed questionnaire, which also included questions about patients' attitudes towards their health. The SF-36 international quality of life questionnaire was used to score quality of life. Based on the results of the study, 280 patients diagnosed with NMOSD were surveyed in 21 regions of the Russian Federation.Results. Most patients with NMOSD who are observed by neurologists receive specialised treatment, but half of all patients with NMOSD currently experience some difficulties in obtaining drug therapy. Over the past year, 28.6% of respondents reported an improvement in their health, 39.6% reported no change, and 31.8% reported a deterioration. Self-assessment of health status declines sharply in patients over 55 years of age. The majority (74%) of patients report a decline in vision. Every second patient noted a decrease in vision at the onset of the disease. Severe movement disorders are characteristic, and for the majority (91%) of patients with NMOSD, strenuous physical activities such as running and weight training are not possible. Patients with disability groups I or II are more limited in their physical and mental resources. Patients receiving treatment significantly better assess changes in their health over the past year, both physical and psychological. Those who receive specialized drug therapy have a much better perception of their own health and its prospects. The SF-36 quality of life indices for NMOSD are significantly lower than normal, primarily in terms of physical condition, but also in terms of psychological well-being.Conclusion. In NMOSD, there are pronounced changes in the quality of life of patients, both according to the original questionnaire and according to the SF-36 scale. Receiving timely and adequate treatment significantly improves these indicators and the prognosis.

  • Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)

    by A.N. Boyko, V.V. Gosteva, M.A. Omarova, I.S. Lozovskaya, S.A. Sivertseva, N.N. Spirin, E.L. Turova, E.A. Dubchenko, S.A. Belov, M.A. Sherman, et al.

    Objective. A nationwide examination of blood relatives of MS patients using free brain MRI for possible detection of RIS and subsequent early diagnosis of MS. Material and methods. In more than 60 regions of the country, relatives of the first degree of kinship (children and siblings) aged 18—50 years of patients with an undisputed diagnosis of MS according to the McDonald criteria in 2017 who were receiving DMTs were called for a free MRI scan of the brain. When focal changes were detected, additional analysis was performed to exclude non-specific vascular changes, migraines, and follow-up was performed for everyone. If RIS was suspected, participants were necessarily referred for inpatient examination to the neurological department No. 2 Federal Medical Center for Brain and Neurotechnology or other large MS centers (by territorial affiliation) for repeated MRI of the brain and spinal cord with contrast, clinical assessment and determination of oligoclonal IgG in cerebrospinal fluid (type of synthesis). Results. For 3 years, information was collected on the results of 416 MRI examinations of healthy first-degree relatives (children and siblings) aged 18—50 years. MRI results. The majority of healthy relatives of the patients (74.6%) showed no focal changes in brain tissue. In 56 examined patients (14.5%), nonspecific or vascular changes were detected that did not imply a demyelinating process. However, 48 people (11.5%) had changes that required additional examination. Only half of them reached the Federal Medical Center and other large centers (the entire survey was proposed to be conducted only within the framework of compulsory medical insurance). Of the 24 patients, 14 were diagnosed with MS and recommended to start treatment urgently. Among the risk factors, it should be noted the transmission of the disease from the mother, the presence of OCI in the CSF, the presence of hypointernative foci on T1-VI, even without accumulation of contrast, as well as the detection of foci in the spinal cord. Conclusion. It is necessary to strengthen monitoring of family members of MS patients in order to take timely measures in case of transition from RIS to MS, without starting the course of infection.

  • Open Access

    Characteristics of the basal psychoautonomous indicators in patients after coronary artery stent placement at various stages of rehabilitation

    by Ruslan A. Mirzoev, Svetlana V. Malchikova, Mikhail A. Sherman

    Background: Clinically significant psychoautonomous syndrome, along with other modifiable factors (obesity, dyslipidemia, low physical activity, smoking, arterial hypertension, etc.) increases the risk of development and progression of coronary artery disease (CAD). In particular, patients who have undergone coronary interventions and have a higher anxiety level are prone to the development of CAD complications. Aim: To characterize the basal parameters of clinically significant psychoautonomous syndrome and their changes over time under combination therapy, including anxiolytics, at various stages of rehabilitation of the patients after endovascular myocardial revascularization. Materials and methods: This open-label randomized controlled prospective study included 60 patients aged 45 to 75 years admitted to our in-patient department for rehabilitation treatment after coronary stent placement. The patients from the intervention group (n = 30), in addition to basic treatment for CAD, were administered anxiolytic therapy (alimemazine tartrate at daily dose of 12.5 to 25 mg i. m. at the early rehabilitation step and at 5 to 10 mg during their out-patient follow-up). The in-patient study period included 3 study visits (at admittance, i. e., Day 1, at Days 5 or 6, and at discharge at Day 10 to 14). Two further study visits were performed during the out-patient rehabilitation period at Days 30 and 60. At each visit, the emotional state, sleep quality, subjective signs of autonomous dysregulation, autonomous background and suprasegmental vegetative regulation, including temporal and spectral indicators of heart rate variability, were evaluated. Results: After endovascular myocardial revascularization (the in-patient study period, Day 1) patients of the intervention and control groups (n = 30 in both groups) demonstrated comparable moderate levels of state anxiety (median [Q1; Q3]: 42 [40; 46] and 42 [36; 43], respectively) and trait anxiety (45 [41; 48] and 42 [40; 46], associated with insomnia (PSQI score: 8 [6; 12] and 6 [3; 9]) and autonomous imbalance (SDNN: 73 [61; 89] and 70 [44; 95]) with a shift to sympathetic hyperactivity. Addition of an anxiolytic initiated the regression of psychoautonomous abnormalities already by the end of the early in-patient rehabilitation period) (Days 10 to 14), with a subsequent decrease in state anxiety to 36 [33; 39] and trait anxiety to 33 [32; 37] (p 0.001), regression of insomnia according to PSQI to 2 [2; 4] (p 0.001), and an improvement of autonomous balance (SDNN) to 113 [81; 132] (p 0.001) at days 45 to 60 of the outpatient follow-up. The only adverse event in the patients receiving the treatment for psychoautonomous dysfunction was increased sleepiness at daytime, which was registered in most of them at initiation of the therapy for 2 to 3 days and did not require any dose modification. There were no other clinically significant adverse events, including cardiovascular. Conclusion: Patients with an increased level of anxiety after endovascular myocardial revascularization are characterized by an autonomous imbalance with sympathetic hyperactivity. Addition of an anxiolytic to the basic treatment for CAD allows for a reduction of both components of the psychoautonomous syndrome, which may be an additional factor for successful patient rehabilitation and as a consequence for the prevention of CAD progression.


  • Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population

    by S.A. Sivertseva, A.M. Prilenskaya, E.V. Popova, E.L. Turova, L.I. Volkova, I.V. Smagina, E.YU. Elchaninova, A.I. Afanas’eVa, Z.A. Goncharova, E.A. Markova, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить степень тяжести и частоту возникновения инфузионных реакций (ИР) на фоне терапии препаратом алемтузумаб у пациентов с высокоактивным течением рассеянного склероза (ВАРС) в российской популяции. МАТЕРИАЛ И МЕТОДЫ В данном ретроспективном исследовании были проанализированы данные 50 пациентов с ВАРС из 6 региональных центров РС России, получивших по два курса алемтузумаба в период с 2018 по 2022 г. РЕЗУЛЬТАТЫ Из всех ИР чаще всего отмечалось появление высыпаний по типу крапивницы (n=27), преимущественно легкой степени тяжести (70,6%). На втором месте по частоте возникновения оказалась головная боль (n=17, 34%). При сравнении группы пациентов, которым проводилась музыкотерапия (МТ), и тех, кто получал алемтузумаб без МТ, статистически значимой разницы частоты и тяжести ИР не было. ЗАКЛЮЧЕНИЕ У всех пациентов были зарегистрированы ИР разной степени выраженности. Отмечалось уменьшение балла по шкале инвалидизации EDSS. МТ не оказала влияния на возникновение ИР и степень их выраженности.

  • Open Access

    Diagnostic criteria and treatment of neuromyelitis optica spectrum disorders (NMOSD)

    by T. O. Simaniv, K. Z. Bakhtiyarova, A. N. Belova, Z. A. Goncharova, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, T. N. Trushnikova, E. L. Turova, T. I. Khaibullin, et al.

    Neuromyelitis optic spectrum disorders (NMOSD) are rare, severely disabling diseases of the central nervous system. They are characterized by periodic, unpredictable exacerbations that lead to an accumulation of irreversible neurologic damage. Despite existing possibilities for diagnosing NMOSD, it can be difficult to make the correct diagnosis in clinical practice. Current treatment options for NMOSD include drugs that affect the pathogenesis of the disease, including complement C5 inhibitors, with which experience is still limited, but published data from clinical trials demonstrate high efficacy of these drugs with an acceptable safety profile. The article reviews the main current approaches to the diagnosis and treatment of NMOSD.


  • Open Access

    Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia

    by A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, et al.

    Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease of the central nervous system. Now 2.8 million people in the world suffer from MS, since 2000 every 5 years there has been an increase in the number of MS patients by 10%. At the same time, the number of cases with highly active MS (HAMS) is increasing, i.e. cases of MS with two or more exacerbations without taking specific pathogenetic therapy or one exacerbation during taking MS disease-modifying therapies (DMTsMS), which is accompanied by the corresponding MRI data of the brain and spinal cord (presence of new or active lesions). Previously, there were no studies of quality of life (QoL) in this subgroup of patients in the world.Objective: to compare the QoL indicators of patients with HAMS with those of healthy people and patients with a typical course of relapsingremitting MS (RRMS).Patients and methods. The study included data on 518 patients from 14 regions of the Russian Federation for 2020–2021 years, in whom HAMS was confirmed during a second examination. We used the results of the analysis of clinical data from neurologists and data from questionnaires filled out by patients with HAMS. Two questionnaires were used in the work – the general (non-specific) Questionnaire for assessing the QoL, SF-36 (The MOS 36-item Short-Form Health Survey) and a special questionnaire for MS patients – MusiQoL (Multiple sclerosis Quality of Life).Results and discussion. Almost all indicators of QoL in HAMS were below the control. When compared with the typical course of RRMS, a more pronounced decrease in daily activity indicators, a significant impact of clinical symptoms on QoL, a negative attitude of patients towards the healthcare system, and a low overall health index were noted. Pearson correlation analysis revealed a stronger effect on QoL parameters of the frequency of exacerbations in HAMS than in RRMS.Conclusion. The data obtained in the study indicate the need for more active management of patients with HAMS using second-line DMTsMS.


  • Open Access

    Rehabilitation of patients with progressive forms of multiple sclerosis

    by S. A. Sivertseva, K. S. Anfilofyeva, A. V. Zotova, A. A. Belkin, M. A. Sherman

    Rehabilitation has an important place in the treatment and management of patients with multiple sclerosis (MS). Currently, active research is being carried out in the field of telerehabilitation, extended rehabilitation and staged rehabilitation.Objective: to study the results of staged motor rehabilitation, which is a combination of methods of inpatient rehabilitation, telerehabilitation and home rehabilitation, as links in a chain to maintain rehabilitation potential for a longer period and, if possible, maintain the level of physical activity and quality of life of patients.Patients and methods. The study included 53 patients with progressive forms of MS, who were divided into the main (n=28) and control (n=25) groups. Intensive rehabilitation was carried out, supplemented by telerehabilitation and home rehabilitation. The condition of all patients was assessed using validated scales: the Beck questionnaire, the suicide scale, the Multiple Sclerosis Quality of Life-54 Questionnaire (MsQol-54), the Rankin scale, the Rivermead mobility index, the Barthel index. Physical activity tests were performed – Berg's balance test, 25-foot and 6-minute walk test, five squats, nine-hole peg tests. Cognitive functions were assessed using the Montreal Cognitive Assessment (MoCA test), Symbol Digit Modalities Test (SDMT).Results and discussion. Statistically significant improvement 12 weeks after the end of intensive rehabilitation was noted in the nine-hole peg test, the five squats test, the Berg balance test, the Rivermead mobility index, and the pain level on the visual analog scale. Conclusion. The obtained results suggest that the staged rehabilitation of patients with progressive forms of MS helps to maintain the rehabilitation potential for a long time.


  • Dance therapy in the rehabilitation of neurological diseases

    by S.A. Sivertseva, K.S. Anfilofeva, A.V. Zotova, M.A. Sherman, M.E. Guseva, A.N. Boyko

    A literature review of clinical trials on the effectiveness of the use of dance movement therapy in patients with neurological diseases is presented. A systematic review and meta-analysis of the effectiveness of dance movement therapy on non-motor manifestations of Parkinson's disease is presented. Dance movement therapy was found to have a significant positive effect on cognitive impairment, but no effect on depression, fatigue, and apathy. The effectiveness of dance movement therapy in post-stroke rehabilitation is shown. The data of a systematic review are presented, which found that dance movement therapy is effective not only in the rehabilitation of Parkinson's disease and stroke, but also in the rehabilitation of patients with multiple sclerosis, Huntington's disease and the consequences of spinal cord injury.